LeonaBio Secures $90M Financing at Premium, Acquires Phase 3 Breast Cancer Asset, Extends Runway
Summary
LeonaBio announced a transformative $90 million private placement financing at a premium, acquired a Phase 3 breast cancer drug license, and extended its cash runway into 2028, significantly bolstering its financial position and pipeline.
Key Events
-
Secured $90 Million Private Placement
LeonaBio received $90 million in gross proceeds from a private placement of common stock and warrants, priced at a significant premium to the December 17, 2025 closing price of $6.35 per share. Warrants could provide up to an additional $146 million.
-
Acquired Phase 3 Breast Cancer Program
The company acquired an exclusive global license for Lasofoxifene, a Phase 3 selective estrogen receptor modulator (SERM) for metastatic breast cancer, diversifying its pipeline into a multi-billion dollar market.
-
Extended Cash Runway into 2028
The financing provides sufficient capital to support the Lasofoxifene development program through topline data and extends the company's operational runway into 2028.
-
Advanced Pipeline Milestones
LeonaBio expects to complete enrollment for the Phase 3 Lasofoxifene trial in 4Q 2026 with topline data in 2H 2027, and is on track to initiate a Phase 2 ATH-1105 study for ALS in 2H 2026.
Analysis
LeonaBio has announced a transformative business update, securing $90 million in private placement financing at a significant premium to its prior trading price. This substantial capital infusion, with the potential for an additional $146 million from warrants, provides critical funding into 2028, significantly de-risking the company's operations. Concurrently, the acquisition of an exclusive license for the Phase 3 Lasofoxifene program diversifies its pipeline into a multi-billion dollar breast cancer market, alongside continued progress in its ATH-1105 ALS program. This strategic move, following a recent name change, positions LeonaBio for accelerated clinical development and long-term growth.
At the time of this filing, LONA was trading at $9.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.4M. The 52-week trading range was $3.60 to $50.74. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.